Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening Products

Groundbreaking Artificial Heart Implanted At UMDNJ-Robert Wood Johnson Medical School And Robert Wood Johnson University Hospital
Robert Wood Johnson University Hospital and UMDNJ-Robert Wood Johnson Medical School jointly announce the successful implant of the AbioCor® Total Replacement Heart, the world"s first completely self-contained, fully implantable artificial heart, as well as the first internal artificial organ. The surgery was led by Mark Anderson, MD, associate professor of surgery at UMDNJ-Robert Wood Johnson Medical School and chief of the section of cardiac surgery at both the medical school and Robert Wood Johnson University Hospital, and assisted by Juan Plate, MD, assistant professor of surgery at UMDNJ-Robert Wood Johnson Medical School and an attending surgeon at Robert Wood Johnson University Hospital. Robert Wood Johnson University Hospital is one of only three centers nationwide approved to perform the surgery and the only one in the New York and Philadelphia areas. Dr. Anderson is one of a handful of physicians nationwide trained to perform this procedure. This is the first time the AbioCor has been implanted in a patient since the completion of clinical trials and approval by the Food and Drug Administration.
generic viagra online
Athletes And Weekend Warriors Can Keep Playing After Shoulder Joint Replacement According To Study
Replacing a joint in any part of the body often leads to a long recovery process and the possibility of not being able to return to a sport or activity. However, a new study presented at the American Orthopaedic Society for Sports Medicine"s (AOSSM) Annual Meeting in Keystone, Colorado, (July 9 -12) presents findings that even an older individual who receives a total shoulder joint replacement can return to full participation within approximately six months of surgery.
News of the day
AdvanDx Receives FDA 510(k) Clearance For GBS PNA FISH(R) For Rapid Detection Of Group B Strep From Lim Broths
AdvanDx announced it received FDA 510(k) clearance for GBS PNA FISH(R) for detection of Streptococcus agalactiae, aka Group B Strep, from turbid Lim Broths inoculated with vaginal and rectal swabs obtained from pregnant women between 35 and 37 weeks gestation. The 90 minute molecular diagnostic test enables rapid and highly sensitive detection of Group B Strep from Lim Broths to help detect colonization in pregnant women.
Sexual Health

Polymorphism In Endostatin, An Angiogenesis Inhibitor, And Prostate Cancer Risk And Survival: A Prospective Study

UroToday.com - Angiogenesis is the process of new blood vessel formation in tumors, facilitating their growth. Endostatin is a cleavage product of collagen and is a potent inhibitor of endothelial cell proliferation and migration. Endostatin causes apoptosis in endothelial and tumor cells. Prostate cancer expresses angiogenic factors. A missense mutation in the coding region for endostatin has been described, but the polymorphism affects protein conformation rather than protein expression. Cellular assays suggested that the result is impaired endostatin binding to laminin, a basement membrane protein. In an online article in the International Journal of Cancer, Dr. Lorelei Mucci and colleagues present data from the Physicians" Health Study examining the D104N endostatin polymorphism in relation to prostate cancer risk and survival. The Physicians" Health Study was a randomized trial of aspirin and beta-carotene supplementation among 22,071 physicians ages 40-84 that was initiated in 1982. A total of 14,916 participants had samples available for this nested case-control study. The analysis identified 544 incident prostate cancer cases and 678 controls for polymorphism genotyping. Among the control men, 84.2% were wildtype homozygous (DD), 14.5% were heterozygous (DN), and 1.3% were homozygous carriers of the rare allele (NN). Carriage of the polymorphic N allele was not associated with risk of total prostate cancer risk. There was no evidence that the endostatin D104N polymorphism was associated with prostate cancers diagnosed at a younger or older age. There was also no association between carriage of the N allele and development of lethal prostate cancer. Participants whose prostate cancer contained the polymorphic allele were less likely to be overweight or obese (26%) compared to men with the DD genotype (47.8%). This large study observed no overall association between the D104N endostatin polymorphism and prostate cancer risk or prognosis. Mucci LA, Stark JR, Figg WD, Schumacher F, Li H, Abe M, Hennessy K, Stampfer MJ, Gaziano JM, Ma J, Kantoff PW Int J Cancer. 2009 Mar 11. (Epub ahead of print) 10.1002/ijc.24423 Written by UroToday.com Contributing Editor Christopher P. Evans, MD, FACS UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice. To access the latest urology news releases from UroToday, go to: www.urotoday.com Copyright © 2009 - UroToday


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009